XOMA 3AB Enters Phase 1 Clinical Testing

XOMA Ltd. XOMA today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has informed the Company that it is initiating a Phase 1 clinical trial for XOMA 3AB, XOMA's novel formulation of three antibodies designed to prevent and treat botulism poisoning, among the most deadly bioterror threats. The Phase 1 trial is a double-blind, dose escalation study of a single administration of XOMA 3AB or placebo in approximately 24 healthy volunteers, to be conducted at Johns Hopkins University under an investigational new drug application filed by NIAID with the Food and Drug Administration. The objectives of the study are to assess safety and tolerability and determine the pharmacokinetic profile of XOMA 3AB.